Compositions and methods for tumor immunotherapy
AssigneeCheckmate Pharmaceuticals, Inc.
InventorsArthur Krieg, Aaron Morris, David Mauro, George Weiner, Mohammed Milhem
Life of this patent
Estimating the term…
Abstract
Provided are compositions and methods for treating cancer using administration of certain volumes of CpG oligonucleotides (CpG ODN) and, optionally, administration of a checkpoint inhibitor such as an anti-PD-1 antibody, an anti-PD-L1 antibody, and/or an anti-CTLA-4 antibody. In preferred embodiments, the CpG ODN are selected based on their propensity to induce high amounts of interferon alpha (IFN-a) and T-cell activation relative to interleukin-10 (IL-10) and B-cell activation. In certain embodiments, the methods further include pretreatment with radiotherapy, to potentiate the combination immunotherapy.
Claims5
A method of treating lymphoma in a subject, said method comprising administering to the subject at least one dose of a composition comprising a toll-like receptor 9 (TLR9) agonist,
- wherein the TLR9 agonist comprises an A-class CpG DNA comprising the sequence of SEQ ID NO:
- 82;
- wherein the TLR9 agonist is formulated as a virus-like particle (VLP);
- wherein the composition comprising the TLR9 agonist is administered by intratumoral or peritumoral injection;
- wherein the composition comprising the TLR9 agonist is administered at a dose of about 1 mg to about 100 mg per administration;
- and
- wherein the composition comprising the TLR9 agonist is administered in a volume of 5 mL.
Dependencies are inferred from the claim text.